TrialSignal
Clinical trial intelligence report
Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT06355908-Jul 28, 2026
NCT ID
NCT06355908
Status
SUSPENDED
Phase
PHASE1
Sponsor
Yang Zhang
Executive brief
Investment-Ready Snapshot
Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma is a PHASE1 clinical asset sponsored by Yang Zhang in Glioma. SEO and diligence focus: IL13Rα2 CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06355908
Indication
Glioma
Modality
cell therapy
Target
IL13Rα2 CAR-T
Intervention
IL13Rα2 CAR-T
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.